Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 18;14:87–99. doi: 10.2147/PGPM.S271516

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of LARGE1 on overall survival (OS) in NSCLC. (A) OS difference between NSCLC patients with high and low LARGE1 expression analyzed by the web-tool, Kaplan-Meier plotter, using auto select best cutoff value and the JetSet best probe set (215543_s_at). (B) OS difference between TNM I–III NSCLC patients with high and low LARGE1 expression from TCGA, analyzed by Kaplan-Meier curve with Log rank test. (C) Forest plot of the hazard ratios (HRs) for the associations of increasing LARGE1 expression (serves as a continuous variable) with overall survival (OS) of patients with TNM I–III NSCLC in subgroups stratified by age, gender, smoking history, histology, TNM stage, margin, adjuvant chemotherapy, and adjuvant radiotherapy.